Fig. 3. Comparative RFS in response to combination of RFA and TACE vs

Slides:

Advertisements

Similar presentations

Staging Strategy and Treatment for Patients With HCC

Advertisements

High-Intensity Focused Ultrasound for Hepatocellular Carcinoma Joint Hospital Surgical Grand Round Queen Mary Hospital 19/10/2013.

Current Evidence in Ablative Therapy for Hepatocellular Carcinoma Joint Hospital Surgical Grand Round Dr Chu Ka Wan Queen Mary Hospital.

Joint Hospital Surgical Grand Round 16th Jan 2010 Dr James Fung Department of Surgery United Christian Hospital.

Liver Cancer Management with Y90 Glass Microspheres – TheraSphere Experience and Challenges in HCC Thomas Lauenstein, MD Department of Diagnostic and.

57445 HCC were registered HCC with complete data underwent surgical resection 9577 underwent local ablation therapies 9283 underwent TACE 1150.

In the name of Alla. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis.

Chapter 14: Inference about the Model. Confidence Intervals for the Regression Slope (p. 788) If we repeated our sampling and computed another model,

Intermediate stage HCC treatment options: Y 90 -labelled microspheres.

Fotlos Laspas'. Evangelia Sotiropoitlou'. Sophia Myhna^. Anita Manataki', Paraskevi TsagouW. Iris Tsangaridou', Loukas Thanos'

K Nouso, K Miyahara, D Uchida, K Kuwaki, N Izumi, M Omata, T Ichida, M Kudo, Y Ku, N Kokudo, M Sakamoto, O Nakashima, T Takayama, O Matsui, Y Matsuyama,

Fig. 3. Gadoxetic acid-enhanced MRI in 69-year-old man with chronic hepatitis C.On arterial phase (A), 1.2 cm enhancing nodule is seen in S8 (arrows),

Volume 61, Issue 1, Pages (July 2014)

Fig year-old woman with invasive lobular breast cancer. A

Long-term outcomes of microwave versus radiofrequency ablation for hepatocellular carcinoma by surgical approach: A retrospective comparative study Kit-fai.

From: A Review of Therapeutic Ablation Modalities

Volume 18, Issue 9, Pages (September 2016)

Date of download: 10/29/2017 Copyright © ASME. All rights reserved.

Masatoshi Kudo Clinical Gastroenterology and Hepatology

Fig. 4. First-line treatment according to 2014 KLCSG-NCC Korea Practice Guidelines for patients with HCC, Child-Pugh class A, no portal hypertension, and.

Mansoura University, Mansoura, Egypt

Treatment of hepatocellular carcinoma

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.

Radiofrequency ablation combined with hypertonic saline injection allows creation of coagulation zones similar to those created by microwave ablation Quesada,

Algorithm for the management of hepatocellular carcinoma (HCC)

Algorithm for the management of hepatocellular carcinoma (HCC)

Fig. 4. HCC with hepatobiliary phase (HBP) capsule appearance in 59-year-old female hepatitis B virus carrier. A. 2.8-cm tumor (arrow) in right posterior.

Fig. 5. Receiver operating characteristic curve analyses showing diagnostic accuracy of ADC value for differentiating between bland and malignant PVT.Area.

Barcelona Clinic Liver Cancer (BCLC) staging classification and treatment schedule. Patients with very early hepatocellular carcinoma (HCC) (stage 0) are.

State of the Art in HCC: Immune Checkpoint Modulation

Journal Club Leona von Köckritz

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Fig. 3. Sub-centimeter-sized HCC in 56-year-old man with chronic hepatitis B. Gadoxetic acid-enhanced MR image demonstrates 0.8-cm nodule (arrows) in right.

Konstantinos C. Siontis et al. JACEP 2016;2:

Hepatocellular Carcinoma: Overcoming Challenges in Disease Management

Fig. 1. HCC in 56-year-old man. A

Volume 68, Issue 4, Pages (April 2018)

Volume 61, Issue 6, Pages (June 2012)

Survival Rates Are Comparable After Radiofrequency Ablation or Surgery in Patients With Small Hepatocellular Carcinomas Hung–Hsu Hung, Yi–You Chiou,

Volume 65, Issue 4, Pages (October 2016)

Correction Journal of the American College of Surgeons

Review of treatment for varicose veins

Treatment of hepatocellular carcinoma

Factors Predicting Recurrence and Postrecurrence Survival in Completely Resected Thymic Carcinoma Yi-Ting Yen, MD, Wu-Wei Lai, MD, Kai-Wei Chang, MD,

G. Ippolito, A. Zumla, S. Lanini Clinical Microbiology and Infection

Volume 127, Issue 6, Pages (December 2004)

Fig. 2. HCC in 82-year-old man with chronic hepatitis C. A-C

Konstantinos C. Siontis et al. JACEP 2016;2:

Lance L. Stein, MD, Marty T. Sellers, MD, MPH

Diagnosis and Treatment of Hepatocellular Carcinoma

KAHBPS , Gyeongju, Korea Long-term outcome after resection of huge hepatocellular carcinoma ≥10 cm: Single-institution experience with 471 patients:

Fig. 2. B1-inhomogeneity-induced variation of pre-contrast R1 in gray matter (reference value, sec-1) and blood (reference value, sec-1). A.

Evolution of liver transplantation for hepatocellular carcinoma

Combined locoregional-immunotherapy for liver cancer

Transcatheter Arterial Chemoembolization Therapy for Patients With Hepatocellular Carcinoma: A Case-Controlled Study Maurizio Biselli, Pietro Andreone,

Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence Christian Toso, Gilles Mentha, Pietro.

Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular.

Fig. 1. Typical CEUS features of HCC in 60-year-old man with history of right hemihepatectomy for HCC.On arterial (A) and delayed (B) phases of CT, 2.3-cm.

Masatoshi Kudo Clinical Gastroenterology and Hepatology

Absolute mortality difference Change in LVEF from baseline

LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium–enhanced MRI LI-RADS version 2018 (v2018) had higher.

C. In the hepatobiliary phase, the lesion shows hypointensity (arrow).

Fig. 3. Modified Look–Locker inversion recovery (MOLLI) with 5(3)3 protocol. MOLLI method features several modifications intended to improve accuracy and.

Fig. 2. Photographs of experimental models and RF ablation system

Model for end‐stage liver disease exception points for treatment‐responsive hepatocellular carcinoma Treatment‐responsive HCC: patient with complete response.

Fig. 3. The relationship between the TTD of the initial treatment and RFS following the repeated treatment. (A, C) AEH and (B, D) early G1. AEH, atypical.

Prognostic effect of complete pathologic response following TACE on HCC patients undergoing liver resection or transplantation Prognostic effect of complete.

Factors Associated With Outcomes and Response to Therapy in Patients With Infiltrative Hepatocellular Carcinoma Neil Mehta, Nicholas Fidelman, Monika.

Partial hepatectomy vs

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Fig. 3. Comparative RFS in response to combination of RFA and TACE vs Fig. 3. Comparative RFS in response to combination of RFA and TACE vs. RFA alone for HCC.Meta-analysis demonstrated that RFA plus TACE therapy was associated with significantly higher RFS than that RFA monotherapy. CI = confidence interval, HCC = hepatocellular carcinoma, RFA = radiofrequency ablation, RFS = recurrence-free survival, SE = standard error, TACE = transcatheter arterial chemoembolizaton Fig. 3. Comparative RFS in response to combination of RFA and TACE vs. RFA alone for HCC.Meta-analysis demonstrated that RFA plus TACE therapy was associated with significantly higher RFS than that RFA monotherapy. CI = confidence interval, HCC = hepatocellular carcinoma, RFA = radiofrequency ablation, RFS = recurrence-free survival, SE = standard error, TACE. . . Korean J Radiol. 2016 Jan-Feb;17(1):93-102. http://dx.doi.org/10.3348/kjr.2016.17.1.93